Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

success fee.

    Corporate Update

    - As of 1 July 2009, ThromboGenics was promoted to the NEXT 150
      index on the Euronext stock exchange, reflecting the strong share price
      performance and progress that the Company has made. The NEXT 150 index
      comprises mid to large capitalization stocks on the Euronext exchange.
      The index consists of the 150 next largest stocks following the
      Euronext 100 index and includes stocks from the Amsterdam, Brussels,
      Lisbon and Paris exchanges of Euronext.

      The inclusion of the Company in the NEXT 150 index also
      follows the Company entering the VLAM-21 index earlier in the year,
      which is a capitalized-weighted index of the 21 most capitalized
      Flemish stocks that are traded on a stock exchange.

    - Cross-border merger of ThromboGenics NV and ThromboGenics Ltd
      finalized, leading to a streamlined legal structure and cost savings.

    - ThromboGenics has continued to strengthen its in-house
      expertise, following the strategic hires announced at the time of the
      Company's first quarter 2009 Business Update. In June, Dr. Clive Long
      joined ThromboGenics as Head of Pre-Clinical Program Management. Dr.
      Long joins from Schering-Plough, where he was Proof-of-Concept Leader
      and has 26 years experience working for large pharmaceutical companies
      in research and development.


    Financial Overview
    Revenue and Results

In the first half of 2009, ThromboGenics achieved total revenue of EUR3.6 million, nearly all of which came from its out-licensing activities. Within this amount, EUR3 million came from the first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. In the same period of 2008, ThromboGenics had revenues of EUR30.3 million due to the upfront payment from Roche which resulted from the signi
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Charm Sciences ... test for the Detection of Aflatoxin M1 in raw ... receive independent third party validation. The peer reviewed report ... of the Institute for Agricultural and Fisheries Research (ILVO-T&V) ... , Aflatoxin B1, the most toxic aflatoxin and ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Inc., a division of GE Industrial Systems, announced ... a Green Bay manufacturing software development company. , ... Execution Systems (MES) technology for the manufacturing of ... as well as for pulp and paper products. ...
... to fighting breast cancer, and GE Medical Systems, headquartered ... AD and Second Look Digital are computer-aided detection (CAD) ... digital mammography system. CADx Systems, Inc. developed the Second ... the review of breast exams. , ,GE is ...
... until he gets to the better drugs, faster part of ... behind the Madison-based companys products is likely to hit the ... age when diseases and treatments become as common in conversation ... and a half-year-old company that Vodenlich joined as president earlier ...
Cached Biology Technology:Green Bay Software Company Purchased by GE 2New Technology in Fight against Breast Cancer 2Chipping Away at Drug Development 2Chipping Away at Drug Development 3
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... the U.S. Department of Energy,s Brookhaven National Laboratory have ... against human adenovirus, a cause of ailments ranging from ... published in FEBS Letters , a journal of ... researchers sifted through thousands of compounds to determine which ...
... from Uppsala University, Sweden, show that the key to ... and Creutzfeldt-Jakob disease may lie in the ribosome, the ... recently published in the Journal of Biological Chemistry ... by misfolding of prion proteins. Examples of prion diseases ...
... that has sickened thousands in Haiti came from a single ... the past three years as some have thought, according to ... open-access journal of the American Society for Microbiology. ... findings that indicate Vibrio cholerae bacteria were introduced ...
Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3The ribosome -- a new target for antiprion medicines 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3
MAGP-2 (C-19)...
Laminin gamma-2 (G-16)...
... Proliferation Kit, For 100 slides. Immunocytochemistry.Sample ... in vitro tissue labeling.Recommended cell number: ... (labeling 1-2 hours).Store at 2-8 C ... Category: Drug Screening & Cellular Assays, ...
Dysadherin 2 (L-15)...
Biology Products: